Genotoxicity of Water Extract from Bark-Removed Rhus verniciflua Stokes

Sung-Bae Lee 1,†, Jin-Seok Lee 1,†, Jing-Hua Wang 1, Jin-Seok Lee 1,†, Jing-Hua Wang 1, Min-Young Kim 2, Yung-Hyun Choi 2, Hwa-Dong Lee 3 and Chang-Gue Son 1,*

1 Institute of Bioscience & Integrative Medicine, Daejeon University, 176 split 75 Daedeokdae-ro Seo-gu, Daejeon 35225, Korea; sky161300@naver.com (S.-B.L.); neptune@dju.kr (J.-S.L.); ewccwang@gmail.com (J.-H.W.)
2 Department of Biochemistry, Dong-eui University College of Korean Medicine, Busan 47227, Korea; illytoo365@deu.ac.kr (M.-Y.K.); choiyb@deu.ac.kr (Y.-H.C.)
3 National Institute for Korean Medicine Development, Gyeongsan-si 38540, Korea; herb@nikom.or.kr
* Correspondence: ckson@dju.ac.kr; Tel.: +82-42-257-6397
† These authors contributed equally to this work.

Abstract: Rhus verniciflua Stokes (RVS) has been traditionally used as an herbal remedy to support the digestive functions in traditional Korean medicine. Additionally, the pharmacological effects of RVS, including antioxidative, antimicrobial and anticancer activities, have been well-reported. The genotoxicity of RVS, however, is elusive; thus, we evaluated the genotoxicity of RVS without bark (RVX) for safe application as a resource of functional food or a medical drug. To evaluate the genotoxicity of RVX, we used a bacterial reverse mutation test, chromosomal aberration test and comet assay, according to the “Organization for Economic Co-operation and Development” (OECD) guidelines. Briefly, for the reverse mutation test, samples (5000, 1667, 556, 185, 62 and 0 µg/plate of RVX or the positive control) were treated with a precultured strain (TA98, TA100, TA1535, TA1537 or WP2uvrA) with or without the S9 mix, in which RVX partially induced a reverse mutation in four bacterial strains. From the chromosomal aberration test and comet assay, the RVX samples (556, 185, 62, 20 and 0 µg/mL of RVX or the positive control) were treated in a Chinese hamster ovary cell line (CHO-K1 cells) in the conditions of the S9 mix absent or S9 mix present and in Chang liver cells and C2C12 myoblasts, respectively. No chromosomal aberrations in CHO-K1 or DNA damage in Chang liver cells and C2C12 myoblasts was observed. In conclusion, our results suggest the non-genotoxicity of RVX, which would be helpful as a reference for the safe application of bark-removed Rhus verniciflua Stokes as functional raw materials in the food, cosmetics or pharmaceutical fields.

Keywords: genotoxicity; rhus verniciflua stokes; safety; reverse mutation; chromosomal aberration

1. Introduction

Medicinal plants have been used in traditional medicine to treat various health problems from ancient times [1]. According to “Report Ocean”, the herbal products world market was estimated at 120 billion USD in 2019; this amount will grow up to 200 billion USD in 2024 [2]. In general, herbal products have been perceived by the public as relatively low risk. However, the continuous use of herbal products raised some concerns for the potential risks of these substances [3]. One review reported that 19 of 50 herbs had moderate or severe adverse effects [4]. Especially, hepatotoxicity or renal toxicity frequently occur as toxic effects caused by medicinal herbs [5,6]. These potential risks can occur by contamination, adulteration, the misidentification of herbs and interaction with other herbs, as well as the inherent toxicity of herbs; therefore, safety evaluations and the quality management of herbal products should be necessary for safe use [7].

The genotoxicity of herbal products sometimes becomes a potential risk in health [8,9]. In genetics, genotoxicity encompasses the property of chemical agents that damages the
genetic information, causing mutations that may lead to cancer. The genotoxic substances can affect indirectly or directly damaged DNA, and these genetic properties can be passed to the next generation [9,10]. In several clinical studies, it has been reported that herbal products with genotoxicity could be risky, especially for pregnant women [11,12]. Thus, the “Korean Ministry of Food and Drug Safety” (MFDS) has recently announced a guideline (guidebook no. 2017-0290-02) that requires evaluation of the genotoxicity of new or modified herbal medicinal formulae [13].

*Rhus verniciflua* Stokes (RVS) has been traditionally used to treat mainly gastrointestinal disorders [14,15]. Several fractions and allergen-removed extracts from RVS have proven pharmacological effects, such as antioxidant [16,17], antimicrobial [18,19] or anti-inflammatory effects [20,21]. In addition, anticancer activities of RVS in allergen-removed extracts have been reported in both experimental [22–24] and clinical studies [25]. We also reported the antiemetic and myelo-protective effects of allergen-removed RVS extracts using a cisplatin-injected animal model [26].

In fact, RVS contains urushiol, a typical allergenic compound, mainly in the bark [27], which limits the medicinal application of this plant [28]. Several strategies to remove urushiol, such as high-temperature treatment, fermentation and fractionation, are being developed for application in herbal medicines [29–31]. The allergen-free RVS has been evaluated for safety and efficacy in animal and clinical studies [32–34]. The urushiol-free RVS is also expected to be used for foods and cosmetics [35]. However, the genotoxicity of RVS has not been examined to date. In the present study, we conducted two in vitro genotoxicity tests, a bacterial reverse mutation and mammalian chromosomal aberration test, on the water extract of RVS without bark (RVX).

### 2. Results

#### 2.1. Fingerprint Analysis of RVX

From the analysis using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), four main compounds of RVX were identified at retention times of 6.91, 9.17, 10.22 and 12.00 min for fustin, fisetin, sulfuretin and butein, respectively (Figure 1A,B). Their molecular weights were confirmed as follows: fustin, 288.25 g/mol, fisetin, 286.23 g/mol, sulfuretin, 270.24 g/mol and butein, 272.25 g/mol. We also obtained semi-quantitative data for them: fustin, 17.3 mg/g, fisetin, 47.98 mg/g, sulfuretin, 3.36 mg/g and butein, 0.47 mg/g (Figure 1C). Both urushiol 1 and urushiol 2 were not detected in RVX (Figure 1A,B).

#### 2.2. Determination of Reverse Mutation in Bacterium

The RVX (62, 185, 556, 1667 and 5000 µg/plate) were treated for five bacterial strains (TA100, TA1535, WP2uvrA, TA98 and TA1537) under the absence or presence of the S9 mix. Regardless of whether the S9 mix was present, the cytotoxicity of RVX not observed in all strains. Under the absence of S9 mix, the RVX treatment significantly increased the number of colonies in the TA100 strain (from 62 µg/plate, except 185 µg/plate, p < 0.001) and TA98 and TA1537 strains (from 62 µg/plate, p < 0.05 or p < 0.001) compared to the negative control (Figure 2A). Under the presence of the S9 mix, RVX-related reverse mutations were observed in four strains: TA100 (from 185 µg/plate, p < 0.01 or p < 0.001), WP2uvrA (from 62 µg/plate, p < 0.01 or p < 0.001), TA98 (from 556 µg/plate, p < 0.001) and TA1537 (from 556 µg/plate, p < 0.01 or p < 0.001), respectively (Figure 2B). As expected, all positive control agents (AF2, NaN3, 4-NQO and 9-AA for the condition without the S9 mix and 2-AA and BP for the condition with the 9S mix) showed a significant reverse mutation at least three-fold (p < 0.001; Table 1).
Figure 1. Fingerprint analysis: fingerprint analysis of four (A) standard compounds and (B) *Rhus verniciflua* Stokes without bark (RVX) using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). (C) Quantitative analysis of RVX was performed by ChemStation software.

**Table 1.** Positive agents for bacterial reverse mutations with or without S9 activation.

| Metabolic Activation | Dose (µg/plate) | Number of Colonies/Plate | Frame-shift Type |
|----------------------|-----------------|--------------------------|-----------------|
|                      | Base-Pair Substitution Type | TA100 | TA1535 | WP2uvrA | TA98 | TA1537 |
| S9 mix (−)           | Positive   | AF-2 | NaN₃ | 4-NQO | AF-2 | 9-AA |
|                      | Dose       | 0.01 | 0.5 | 0.25 | 0.1 | 80 |
|                      | Mean ± SD  | 545 ± 31.1 *** | 281 ± 39.3 *** | 318 ± 83.0 *** | 499 ± 9.0 *** | 1185 ± 146 *** |
| S9 mix (+)           | Positive   | 2-AA | 2-AA | 2-AA | BP | 2-AA |
|                      | Dose       | 1.0 | 2.0 | 10.0 | 10.0 | 2.0 |
|                      | Mean ± SD  | 309 ± 76.4 *** | 193 ± 6.4 *** | 263 ± 52.6 *** | 522 ± 90.3 *** | 143 ± 7.5 *** |

Bacterial reverse mutation test was performed in four histidine-requiring *Salmonella typhimurium* strains: TA98, TA100, TA1535 and TA1537 and one tryptophan-requiring *Escherichia coli* strain, WP2uvrA. All data were expressed as the mean ± SD (*n* = 3). *p* < 0.05, **p** < 0.01 or ***p** < 0.001 compared to the negative control (0 µg/plate). NaN₃, Sodium azide; 9-AA, 9-aminoacridine; AF-2, 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide; 2-AA, 2-aminoanthracene; BP, benzo(a)pyrene and 4-NQO, 4-nitroquinoline 1-oxide.
Figure 2. Bacterial reverse mutation test was performed according to the Organization for Economic Co-operation and Development (OECD) guideline number 471. The RVX or positive control was treated for each bacterial strain under the conditions of the S9 mix: (A) absence or (B) presence of the mix after incubation. The revertant colonies were counted, and the above test was repeated in triplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to the negative control (0 µg/mL).

2.3. Determination of Chromosomal Aberration in a Hamster Ovary Cell Line

The RVX (2–5000 µg/mL) were treated to Chinese hamster ovary cell line (CHO-k1) cells under the absence or presence of the S9 mix for a short (18-h recovery after 6-h incubation) or long time (24-h incubation), and the half-maximal inhibitory concentrations (IC$_{50}$) were calculated as 191 and 489 µg/mL in the presence and absence of the S9 mix via the cell viability assay, respectively (Figure 3A). The chromosomal aberration test was performed based on the IC$_{50}$ (maximum 185 and 556 µg/mL in the presence and absence of the S9 mix, respectively). Structural or numerical aberrations of the RVX treatment were not observed, regardless of the presence of the S9 mix (Figure 3B), and the number of chromosomal aberrations were counted (p > 0.05; Table 2). As expectation, the positive chemicals (mitomycin C and cyclophosphamide) significantly induced the chromosomal aberrations (p < 0.001; Figure 3B and Table 2).
Figure 3. (A) Chinese hamster ovary cell line (CHO-K1) cell viability was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (B) Chromosomal aberration CHO-K1 cells were treated RVX or MMC for 24 h for long-term treatment, while cells were treated with RVX or MMC for 6 h, followed by incubation in fresh media for a further 18 h, under the two conditions (absence or presence of the S9 mix) for the short-term treatment. The structural and numerical chromosomal aberrations were counted under an optical microscope. ** p < 0.01 and *** p < 0.001 compared to the negative control (0 µg/mL). MMC, Mitomycin C.

2.4. Determination of DNA Damage in Human and Mouse Cell Lines

To exclude DNA damage by the cytotoxicity of RVX, a cell viability assay was performed at a 20–556 µg/mL concentration of RVX in Chang liver and C2C12 cells. The treatment of RVX did not induce cytotoxicity in the two types of cells (Figure 4B,D). Based on the cell viability results, RVX or 1 mM of H₂O₂ was treated to Chang liver and C2C12 cells. Compared to nontreated cells, no differences of DNA tail length by RVX treatment were observed in both Chang liver and C2C12 cells (Figure 4A,C), while the treatment of H₂O₂ dramatically increased the DNA tail length compared to nontreated cells in two types of cells (Figure 4A,C).
### Table 2. Chromosomal aberrations by *Rhus verniciflua* Stokes without bark (RVX) with or without S9 activation.

| Condition  | Dose (µg/mL) | Aberration (No. in 300 cells) | Aberration Rate (%) |
|------------|--------------|------------------------------|---------------------|
|            |              | Chromatid Breaks | Exchange | Chromosome Breaks | Exchange | PP+ER |                          |
| 0–24 h     |              |                  |          |                  |          |       |                          |
| S9 mix (−) | 0            | 0                | 2        | 0                 | 0        | 0     | 0.67                      |
|           | 20.58        | 1                | 0        | 0                 | 0        | 0     | 0.33                      |
|           | 61.73        | 0                | 1        | 0                 | 0        | 0     | 0.33                      |
|           | 185.19       | 2                | 1        | 0                 | 0        | 0     | 1.00                      |
|           | MMC 0.04     | 9                | 62       | 0                 | 0        | 0     | 23.67 ***                 |
| 6–18 h     |              |                  |          |                  |          |       |                          |
| S9 mix (−) | 0            | 1                | 0        | 0                 | 0        | 0     | 0.33                      |
|           | 20.58        | 1                | 1        | 0                 | 0        | 0     | 0.67                      |
|           | 61.73        | 1                | 1        | 0                 | 0        | 0     | 0.67                      |
|           | 185.19       | 1                | 2        | 0                 | 0        | 0     | 1.00                      |
|           | MMC 0.04     | 12               | 54       | 0                 | 0        | 0     | 22.00 ***                 |
| 6–18 h     |              |                  |          |                  |          |       |                          |
| S9 mix (+) | 0            | 0                | 2        | 0                 | 0        | 0     | 0.67                      |
|           | 61.73        | 0                | 1        | 0                 | 0        | 0     | 0.33                      |
|           | 185.19       | 1                | 0        | 0                 | 0        | 0     | 0.33                      |
|           | CPA 10       | 7                | 64       | 0                 | 0        | 0     | 1.00                      |

Structural (break and exchange in chromatid or chromosome) and numerical aberrations (polyploidy and endoreduplication) were counted in 300 Chinese hamster ovary cell line (CHO-k1) cells. *** *p* < 0.001 compared to the negative control (0 µg/mL). MMC, Mitomycin C; CPA, Cyclophosphamide; PP, Polyploidy and ER, Endoreduplication.

![Figure 4](image-url)

**Figure 4.** (A,C) A comet assay was performed for Chang liver and C2C12 cells after treatment with RVX for 24 h. The images stained with propidium iodide (PI) were captured under a fluorescence microscope. (B,D) The viability of Chang liver and C2C12 cells was determined using the MTT assay. *** *p* < 0.001 compared to the negative control (0 µg/mL).
3. Discussion

Genotoxic substances can lead to malformations or carcinogenesis; therefore, to assess the genotoxicity is a key factor for the protection of human health [36]. For the wide adaptation of RVS as a natural resource for medicinal or food products, we evaluated the genotoxicity of RVS. The genotoxicity of RVS was performed using a reverse mutation test, mammalian chromosomal aberration test and comet assay related to DNA damage, according to the OECD guidelines. In the present data, RVX induced reverse mutations of four bacteria, excluding TA1535, in a bacterial reverse mutation test but not chromosomal aberration in CHO-K1 cells and DNA damage in Chang liver and C2C12 cells.

The reverse mutation test has been used worldwide as an initial screen to determine the mutagenic potential of new chemicals and drugs. In our results, RVX induced mutagenesis on TA98, TA100, TA1537 and WP2uvrA in the conditions of the absence or presence of the S9 mix (Figure 2). These positive results indicated that the tested sample possibly causes a frame shift or point mutation, including the addition, deletion or substitution of one [37]. However, the genotoxic mechanism by which RVX induces these mutations is unclear.

To reverify the above results, we additionally performed chromosomal aberration in a hamster cell line and the comet assay in the human and mouse cell lines. The mammalian chromosomal aberration test was used to identify possible mutagens and carcinogens [38]. Chromosomal mutations cause various genetic diseases, and there is substantial evidence that chromosomal mutations are found in oncogenes and tumor-suppressor genes [39]. As we could expect, two positive chemicals, mitomycin C and cyclophosphamide, significantly induced both structural and numerical aberrations, regardless of the presence of the S9 mix ($p < 0.001$), while they were not observed in the RVX treatment group (Figure 3 and Table 2). In addition, RVX did not show an alteration of DNA in the human and mouse cell lines, according to the results from the comet assay (Figure 4). The comet assay is a versatile and simple technique used to measure DNA damage and repair in individual cells [40]. Oxidative DNA damage by reactive oxygen species (ROS) and free radicals are important in the pathogenesis various diseases, and $\text{H}_2\text{O}_2$, one of the main ROS, is known to cause oxidative DNA damage in various cells [41]. These negative results from both the chromosomal aberration test and comet assay may indicate the absence of possibility of RVX genotoxicity. Like the above descriptions, RVX showed conflicted results in three types of genotoxicity in vitro tests. It has frequently been reported that many noncarcinogens can produce false-positive results in certain genotoxicity assays [42]. If the mammalian chromosomal aberration test and comet assay showed negative outcomes, a positive result in the bacterial reverse mutation test could be denied [43–45].

The bark of RVS mainly contains urushiol, a typical allergenic compound [27], and limits the medicinal application of RVS [28]. As we expected, no urushiol was detected in the sample (RVX, bark-removed RVS) of the present work (Figure 1), and the data was consistent with another study regarding the quantitative analysis of urushiol from bark-removed RVS [46]. Urushiol-free RVS is used as an anticancer remedy in Korea [47,48]. Some herbs are known to have genotoxicity, and the major compounds responsible for genotoxicity are those of the pyrrolizidine alkaloid series [49]. In the UHPLC-MS/MS analysis, fustin, fisetin, sulfuretin and butein were detected as the main compounds in RVX (Figure 1). It is well-known that RVS does not contain pyrrolizidine alkaloid compounds [50]. In contrast to our results, one study reported that water and ethanol extracts from RVS have a genotoxicity [51]; however, the reason may be the presence or absence of a bark. Bioactive compounds from the bark of RVS were also studied by many researchers [27,31,52], but its genotoxic activity is yet unknown. Further studies, including a micronucleus test, would be helpful in verifying the genotoxic safety of bark-removed RVS in the next study.

Taken together, our results from three types of in vitro tests revealed the non-genotoxicity of RVS. Although the present study had limitations, such as no information from in vivo tests, our data would be helpful as a reference for the safe application of bark-removed Rhus verniciflua Stokes as a functional raw material in the food, cosmetic or pharmaceutical fields.
4. Materials and Methods
4.1. Preparation of RVS and Fingerprinting Analysis

Water extract of RVS without bark (RVX) was obtained from Daehan Bio Pharm Inc. (Gyeonggi-do, South Korea). Briefly, 100 kg of the bark, excluding the wooden part of RVS, was boiled in 1000 L of distilled water at 100 °C for 2 h. After centrifugation, the supernatant was filtered through Adventec filter paper (Toyo Roshi Kaisha, Tokyo, Japan). The filtered extract was lyophilized using an Ecospin 3180C (Hanil Science Medical, Daejeon, South Korea). Finally, RVX powder was obtained (final yield: 0.71%) and stored at −70 °C in a deep freezer for future use.

To identify the chemical components of RVX, fingerprinting analysis was conducted using an ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS; Agilent Technologies, Santa Clara, CA, USA). Briefly, five milligrams of RVX were dissolved in 1 mL of 50% methanol, and the solution was filtered. Sample solutions of 10 μL were subjected to UHPLC-MS/MS using an MS Spectrometer (Thermo Fisher Scientific, Santa Clara, MA, USA). Separation was performed using the C18 column (4.6 nm × 150 nm and particle size, 5 μm; Waters, Torrance, CA, USA) at 50 °C. The column was eluted at a flow rate of 0.35 mL/min using water (in 0.1% formic acid) and acetonitrile (in 0.1% formic acid), which were used as mobile phases A and B, respectively. The following gradients were applied: 0 to 1 min, 0–1% B in A, 1–7 min, 1–100% B in A and 7–10 min, 100–1% B in A (linear gradient). The compositional analyses were conducted using a photodiode array at 200–600 nm. The full-scan mass spectra were acquired at 100–1000 m/z in positive and negative modes. The data were acquired by ChemStation software (Agilent Technologies, Wilmington, DE, USA) as compared to the five reference compounds (fustin, fisetin, sulfuretin, urushiol 1 and urushiol 2). Quantitative analysis of the major compounds in RVX was performed using UHPLC-MS/MS.

4.2. Bacterial Reverse Mutation Test

For the bacterial reverse mutation test, 4 histidine-requiring Salmonella typhimurium strains (TA98, TA100, TA1535 and TA1537) and one tryptophan-requiring Escherichia coli strain (WP2μvrA) were obtained from Molecular Toxicology (Boone, NC, USA). A minimal glucose agar plate (Junsei Chemical, Tokyo, Japan), D-( + )-glucose and Vogel-Bonner medium E (10×, Sigma Aldrich, St. Louis, MO, USA) were used. The top agar was combined with NaCl and Bacto agar (BD Korea, Busan, Republic Korea) with 0.5-mM histidine/biotin or 0.5-mM tryptophan (Sigma Aldrich, St. Louis, MO, USA). As the positive control, sodium azide (NaN₃), 9-aminoacridine (9-AA), 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide (AF-2, 0.01 or 0.1 μg/plate), 2-aminoanthracene (2-AA), benzo(a)pyrene (BP) and 4-nitroquinoline 1-oxide (4-NQO) were obtained from Sigma Aldrich (St. Louis, MO, USA) or Wako Chemicals (Richmond, VA, USA).

The tests were performed by Korean Conformity Laboratory (Incheon, Republic of Korea, Test # GT17-00313), according to Organization for Economic Co-operation and Development (OECD) guideline number 471 (adapted on 21 July 1997) and a previous study [53]. The RVX were treated for each bacterial strain under the conditions with or without the S9 mix. Briefly, 0.05 mL of serum-free media; RVX (5000, 1667, 556, 185 and 62 μg/plate) or positive control (AF-2 0.01 or 0.1 μg/plate; NaN₃ 0.5 μg/plate; 4-NQO 0.25 μg/plate; 9-AA 80 μg/plate; 2-AA 1.0, 2.0 or 10 μg/plate or BP 1.0, 2.0 or 10 μg/plate) were mixed with 2.0 mL of top agar and 0.1 mL of the precultured strain (TA98, TA100, TA1535, TA1537 or WP2μvrA) with 0.5 mL of the S9 mix or 0.1-M phosphate-buffered saline (PBS; pH 7.4). The mixture was vortexed and then poured onto a minimal glucose agar plate. After the agar overlay solidified, the plates were incubated for 48 h at 37 °C. After incubation, the revertant colonies were counted. The above test was repeated in triplicate.

4.3. Cell Cultures

CHO-K1 cell, a Chinese hamster ovary cell line, was purchased from the Korean Cell Line Bank (Seoul, Republic of Korea). Chang liver cells (human liver cell line) and
C2C12 myoblasts (mouse muscle cell line) were obtained from the American Type Culture Collection (ATCC, Raymond, VA, USA). CHO-k1 and Chang liver cells were cultured in minimum essential medium (MEM; WelGENE Inc., Kyeong-book, Korea) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Santa Clara, MA, USA) at 37 °C and 5% CO2. The C2C12 myoblast was cultured in Dulbecco’s modified Eagle’s medium (DMEM; WelGENE Inc., Kyeong-book, Korea) containing 10% FBS at 37 °C with 5% CO2.

4.4. Cell Viability Assay

The cell viability was determined by the ability of the mitochondria using conversion from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromides (MTT; Sigma-Aldrich, St. Louis, MO, USA) to formazan dyes. Briefly, CHO-K1, Chang liver and C2C12 cells were cultured in 96-well plates (1×10^4 cells per well), respectively. After overnight, each cell was treated with various concentrations of RVX (from 2 to 5000 µg/mL) for 24 h. Following the incubation, the medium was removed, and the cells were supplemented with fresh medium containing the MTT solution (final concentration of 0.5 mg/mL) into each well and incubated for 3 h at 37 °C with 5% CO2. The MTT was removed, and cells were lysed with 150-µL Dimethyl Sulfoxide. Absorbance was measured at 570 nm using a microplate reader (VersaMax Molecular Devices, Sunnyvale, CA, USA). The optical density of formazan crystals formed in nontreated control cells was used to indicate 100% viability.

4.5. In Vitro Mammalian Chromosomal Aberration Test

The test was conducted by Korean Conformity Laboratory (Incheon, Republic of Korea, Test # GT17-00314) according to OECD guideline no. 473 (adapted on 29 July 2016) and a previous study [53]. Mitomycin C (MMC; Sigma Aldrich, St. Louis, MO, USA) or cyclophosphamide monohydrate (CPA; Abcam, Cambridge, UK) were used as positive control agents for the S9 mix absent or present conditions, respectively. Briefly, the CHO-k1 cells were incubated in 60-mm plates (4×10^4 cells per plate) for 3 days at 37 °C and CO2. For the short-term treatment, cells were treated with RVX (185, 62 and 20 µg/mL) or MMC (0.04 µg/mL) for 6 h under the two condition (absence or presence of the S9 mix). After treatment, cells were washed and incubated in fresh media for a further 18 h. For the long-term treatment, cells were treated RVX (185, 62 and 20 µg/mL) or MMC (0.04 µg/mL) for 24 h. Colcemid (Thermo Fisher Scientific, Santa Clara, MA, USA) was added (10-µg/mL final concentration) at 2 h prior to harvesting. Harvested cells were added to 75-mM potassium chloride (KCL; Sigma Aldrich, St. Louis, MO, USA) and fixed in Carnoy’s solution (methanol:acetic acid, 1:3). Then, the cells were placed on glass slides and stained in 5% Giemsa (Merck, Kenilworth, NJ, USA). The structural and numerical chromosomal aberrations were counted under an optical microscope (Sinjuku, Tokyo, Japan).

4.6. Comet Assay in Human Liver and Mouse Muscle Cells

To determine deoxyribonucleic acid (DNA) damage by RVX, a comet assay was performed according to a previous study [54]. Briefly, the Chang liver and C2C12 cells were washed with PBS, suspended in low-melting agarose (LMA) at 37 °C and then spread on the microscope slides, which were precoated with normal melting agarose. After the agarose was solidified, the slides were covered with LMA and then submerged in lysis solution at 4 °C for 1 h. The slides were incubated in a gel electrophoresis device (Hercules, CA, USA) for 30 min and electrophoresed for 20 min at 30 V and 300 mA. Subsequently, the slides were washed with neutralizing buffer and then stained with propidium iodide (PI) (20 µg/mL, Sigma Aldrich, St. Louis, MO, USA). The images stained with PI were captured under a fluorescence microscope (Carl Zeiss, Oberkochen, Germany).

4.7. Statistical Analysis

Statistical analyses were performed for the bacterial reverse mutation test and in vitro chromosomal aberration test by one-way analysis of variance (ANOVA), followed by Tukey’s HSD (honest significant difference) post-hoc test using SPSS (IBM, San Francisco,
CA, USA). In all analyses, \( p < 0.05 \), \( p < 0.01 \) or \( p < 0.001 \) was used as the threshold to indicate statistical significance. All data were expressed as the mean ± SD.

**Author Contributions:** S.-B.L. wrote the main manuscript text and conducted the experiments. J.-S.L. prepared Figure 1 and the tables. J.-H.W. edited the manuscript. M.-Y.K. and Y.-H.C. prepared Figure 3. H.-D.L. prepared Figure 1. C.-G.S. supervised the manuscript writing and completed the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the National Research Foundation of Korea (grant number: 2019R1A2C2088201).

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare that no conflicts of interest exist. All the authors have approved the final article.

**Sample Availability:** Samples of the Water extract of RVS without bark (RVX) are available from the corresponding author.

References

1. Sen, T.; Samanta, S.K. Medicinal plants, human health and biodiversity: A broad review. *Adv. Biochem. Eng. Biotechnol.* **2015**, *147*, 59–110. [CrossRef]
2. Medium. Available online: https://medium.com/@faisal_44563/global-herbal-medicine-market-growth-2019-2024-ee649dfc3867 (accessed on 21 February 2019).
3. Jordan, S.A.; Cunningham, D.G.; Marles, R.J. Assessment of herbal medicinal products: Challenges, and opportunities to increase the knowledge base for safety assessment. *Toxicol. Appl. Pharmacol.* **2010**, *243*, 198–216. [CrossRef]
4. Posadzki, P.; Watson, L.K.; Ernst, E. Adverse effects of herbal medicines: An overview of systematic reviews. *Clin. Med.* **2013**, *13*, 7–12. [CrossRef]
5. Abt, A.B.; Oh, J.Y.; Huntington, R.A.; Burkhart, K.K. Chinese Herbal Medicine Induced Acute Renal Failure. *Arch. Intern. Med.* **1995**, *155*, 211–212. [CrossRef]
6. Xu, L.; Lin, Q. [Hepatic toxicity of Chinese herbal medicine]. *Zhonghua Gan Zang Bing Za Zhi* **2007**, *15*, 534–535.
7. Zhang, J.; Wider, B.; Shang, H.; Ernst, E. Quality of herbal medicines: Challenges and solutions. *Complementary Ther. Med.* **2012**, *20*, 100–106. [CrossRef]
8. Zhou, J.; Ouedraogo, M.; Qu, F.; Duez, P. Potential genotoxicity of traditional Chinese medicinal plants and phytochemicals: An overview. *Phytother. Res.* **2013**, *27*, 1745–1755. [CrossRef]
9. Schins, R.P.F. Mechanisms of Genotoxicity of Particles and Fibers. *Inhal. Toxicol.* **2002**, *14*, 57–78. [CrossRef]
10. Mei, N.; Guo, L.; Fu, P.P.; Fuscoe, J.C.; Luan, Y.; Chen, T. Metabolism, Genotoxicity, and Carcinogenicity of Comfrey. *Environ. Health B Crit. Rev.* **2010**, *13*, 509–526. [CrossRef]
11. Schins, R.P.F.; Simoes, R.S.; de Jesus Simoes, M.; Girao, M.J.B.C.; Grundmann, O. Pregnancy and herbal medicines: An unnecessary risk for women’s health—A narrative review. *Phytother. Res.* **2018**, *32*, 796–810. [CrossRef]
12. Holst, L.; Nordeng, H.; Haavik, S. Use of herbal drugs during early pregnancy in relation to maternal characteristics and pregnancy outcome. *Pharmacoepidemiol. Drug Saf.* **2008**, *17*, 151–159. [CrossRef]
13. Korean Ministry of Food and Drug Safety. Pre-Clinical Study Guideline of Herbal Medicine. Volume 290. Available online: http://www.nifds.go.kr/brd/m_15/view.do?seq=11381&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=74 (accessed on 2 April 2019).
14. Yoo, H.; Roh, J. *Compendium of Prescriptions from the Countryside (Hyangyakjipseongbang)*; Hangrimchulpansa: Seoul, Korea, 1977; Volume 1433.
15. Luo, X.; Li, S. *Compendium of Materia Medica: Bencao Gangmu*; Foreign Languages Press: Beijing, China, 2003.
16. Lim, K.-T.; Hu, C.; Kitts, D.D. Antioxidant activity of a Rhus verniciflua Stokes ethanol extract. *Food Chem. Toxicol.* **2001**, *39*, 229–237. [CrossRef]
17. Kim, M.-J.; Choi, W.-C.; Barshinkov, A.M.; Kobayashi, A. Anticancer and Antioxidant Activity of Allergen-Removed Extract in Rhus verniciflua Stokes. *Korean J. Med. Crop Sci.* **2002**, *10*, 288–293.
18. Kim, J.-S.; Kwon, Y.-S.; Chun, W.-J.; Kim, T.-Y.; Sun, J.; Yu, C.-Y.; Kim, M.-J. Rhus verniciflua Stokes flavonoid extracts have anti-oxidant, anti-microbial and α-glucosidase inhibitory effect. *Food Chem. Toxicol.* **2010**, *120*, 539–543. [CrossRef]
19. Suk, K.T.; Baik, S.K.; Kim, H.S.; Park, S.M.; Paeng, K.J.; Uh, Y.; Jang, I.H.; Cho, M.Y.; Choi, E.H.; Kim, M.J.; et al. Antibacterial effects of the urushiol component in the sap of the lacquer tree (Rhus verniciflua Stokes) on Helicobacter pylori. *Helicobacter* **2011**, *16*, 434–443. [CrossRef]
20. Moon, J.E.; Shin, J.-H.; Kwon, O.; Kim, J.Y. A Standardized Extract of Rhus verniciflua Stokes Protects Wistar Rats Against Lipopolysaccharide-Induced Acute Inflammation. *J. Med. Food* **2015**, *18*, 1223–1230. [CrossRef]
21. Lee, J.-D.; Huh, J.-E.; Jeon, G.; Yang, H.-R.; Woo, H.-S.; Choi, D.-Y.; Park, D.-S. Flavanon-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritis fibroblast-like synovial cells and in vivo models. *Int. Immunopharmacol.* 2009, 9, 268–276. [CrossRef]

22. Kang, S.-H.; Hwang, I.-H.; Son, E.; Cho, C.-K.; Choi, J.-S.; Park, S.-J.; Jang, B.-C.; Lee, K.-B.; Lee, Z.-W.; Lee, J.H.; et al. Allergen-Removed Rhus verniciflua Extract Induces Ovarian Cancer Cell Death via JNK Activation. *Am. J. Chin. Med.* 2016, 44, 1719–1735. [CrossRef]

23. Kang, Y.; Yoon, S.W.; Park, B. Allergen-removed Rhus verniciflua Stokes suppresses invasion and migration of pancreatic cancer cells through downregulation of the JAK/STAT and Src/FAK signaling pathways. *Oncol. Rep.* 2018, 40, 3060–3068. [CrossRef]

24. Kim, M.S.; Lee, C.W.; Kim, J.-H.; Lee, J.-C.; An, W.G. Extract of Rhus verniciflua Stokes Induces p53-Mediated Apoptosis in MCF-7 Breast Cancer Cells. *Evid. Based Complement. Alternat. Med.* 2019, 2019, 9407340. [CrossRef]

25. Choi, W.; Jung, H.; Kim, K.; Lee, S.; Yoon, S.; Park, J.; Kim, S.; Cheon, S.; Eo, W.; Lee, S. Rhus Verniciflua Stokes against Advanced Cancer: A Perspective from the Korean Integrative Cancer Center; BioMed Research International 2011; Hindawi: London, UK, 2012.

26. Kim, H.-S.; Kim, H.-G.; Im, H.-J.; Lee, J.-S.; Lee, S.-B.; Kim, W.-Y.; Lee, H.-W.; Lee, S.-K.; Byun, C.K.; Son, C.-G. Antiinflammatory and Myeloprotective Effects of Rhus verniciflua Stoke in a Cisplatin-Induced Rat Model. *Evid. Based Complement. Alternat. Med.* 2017, 2017. [CrossRef]

27. Jang, J.Y.; Shin, H.; Lim, J.-W.; Ahn, J.H.; Jo, Y.H.; Lee, K.Y.; Hwang, B.Y.; Jung, S.-J.; Kang, S.Y.; Lee, M.K. Comparison of antibacterial activity and phenolic constituents of bark, lignum, leaves and fruit of Rhus verniciflua. *PLoS ONE* 2013, 8, e700257. [CrossRef]

28. National Institute of Food and Drug Safety Evaluation. Standard and criteria of food Korean Ministry of Food and Drug Safety. Volume 31. Available online: https://www.mfds.go.kr/brd/m_211/view.do?seq=14324 (accessed on 26 April 2019).

29. Chae, J.; Lee, S.; Lee, S. Potential Efficacy of Allergen Removed Rhus Verniciflua Stokes Extract to Maintain Progression-Free Survival of Patients With Advanced Hepatobiliary Cancer. *Explore (NY)* 2018, 14, 300–304. [CrossRef]

30. Jeong, H.J.; Park, J.-H.; Kim, M.-J. Optimization of the extraction process for fermented Rhus verniciflua stokes using response surface methodology. *Food Sci. Biotechnol.* 2016, 25, 179–184. [CrossRef]

31. Kang, S.Y.; Kang, J.-Y.; Oh, M.-J. Antiviral activities of flavonoids isolated from the bark of Rhus verniciflua stokes against fish pathogenic viruses. *In Vitro J. Microbial.* 2012, 50, 293–300. [CrossRef]

32. Lee, J.-C.; Lee, K.-Y.; Kim, J.; Na, C.-S.; Jung, N.-C.; Chung, G.-H.; Jang, Y.-S. Extract from Rhus verniciflua Stokes is capable of inhibiting the growth of human lymphoma cells. *Chem. Toxicol. 2004*, 42, 1383–1388. [CrossRef]

33. Shin, S.-H.; Koo, K.-H.; Bae, J.-S.; Cha, S.-B.; Kang, I.-S.; Kang, M.-S.; Kim, H.-S.; Heo, H.-S.; Park, M.-S.; Gil, G.-H.; et al. Single and 90-day repeated oral dose toxicity studies of fermented Rhus verniciflua stem bark extract in Sprague-Dawley rats. *Food Chem. Toxicol.* 2013, 55, 617–626. [CrossRef]

34. Cheon, S.H.; Kim, K.S.; Kim, S.; Jung, H.S.; Choi, W.C.; Eo, W.K. Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. *Forsch Komplementmed.* 2011, 18, 77–83. [CrossRef]

35. Kim, S.H.; Seo, H.-S.; Jang, B.-H.; Shin, Y.-C.; Ko, S.-G. The effect of Rhus verniciflua Stokes (RVS) for anti-aging and whitening of skin. *J. Food Hyg. Saf.* 2011, 20, 107–111. [CrossRef]

36. Singh, N.; Manshian, B.; Jenkins, G.J.; Griffiths, S.M.; Williams, P.M.; Maffeis, T.G.; Wright, C.J.; Doak, S.H. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. *Biomaterials* 2009, 30, 3891–3914. [CrossRef]

37. Sugiyama, K.-I.; Yamada, M.; Awogi, T.; Hakura, A. The strains recommended for use in the bacterial reverse mutation test. *In Vitro J. Microbiol.* 2009, 55, 721–734. [CrossRef]

38. Kirkland, D.; Reeve, L.; Gatehouse, D.; Vanparys, P. A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. *Mutat. Res. /Genet. Toxicol. Environ. Mutagenesis* 2011, 721, 27–73. [CrossRef]

39. Fei, C.; Zhang, J.; Lin, Y.; Wang, X.; Zhang, K.; Zhang, L.; Zheng, W.; Wang, M.; Li, T.; Xiao, S.; et al. Safety evaluation of a triazine compound nitromezuril by assessing bacterial reverse mutation, sperm abnormalities, micronucleus and chromosomal aberration. *Regul. Toxicol. Pharmacol.* 2015, 71, 585–589. [CrossRef]

40. Jeong, M.H.; Yang, K.; Lee, C.G.; Jeong, D.H.; Park, Y.S.; Choi, Y.J.; Kim, J.S.; Oh, S.J.; Jeong, S.K.; Jo, W.S. In Vitro Genotoxicity Assessment of a Novel Resveratrol Analogue, HS-1793. *Toxicol. Res.* 2014, 30, 211–220. [CrossRef]

41. Choi, C.; Han, D.U. Genotoxicological safety estimate for the Rhus-H. *J. Food Hyg. Saf.* 2005, 20, 18–21.

42. Choi, W.C. *Study on the Safety and Antitumor Activity of Rhus Verniciflua Extract (Nexia)*; Graduate School of East-West Medicine, Kyunghee University: Seoul, Korea, 2006.
48. Jeong, J.-S.; Park, J.-W.; Yoon, S.-W.; Choi, W.-C. Case Report Carcinostatic effect of allergen removed Rhus Verniciflua stokes based Traditional Korean Medicine on a patient with lung adenocarcinoma; single case report. *Orient. Pharm. Exp. Med.* 2008, 7, 573–578. [CrossRef]

49. Chen, T.; Mei, N.; Fu, P.P. Genotoxicity of pyrrolizidine alkaloids. *J. Appl. Toxicol. Int. J.* 2010, 30, 183–196. [CrossRef]

50. Li, M.-C.; Zhang, Y.-Q.; Meng, C.-W.; Gao, J.-G.; Xie, C.-J.; Liu, J.-Y.; Xu, Y.N. Traditional uses, phytochemistry, and pharmacology of Toxicodendron vernicifluum (Stokes) F.A. Barkley—A review. *J. Ethnopharmacol.* 2020, 113476. [CrossRef]

51. Kim, J.-Y.; Oh, S.-W.; Han, D.; Lee, M. Evaluation of Genotoxicity of Water and Ethanol Extracts from Rhus Verniciflua Stokes (RVS). *Toxicol. Res.* 2008, 24, 151–159. [CrossRef]

52. Jeon, W.K.; Lee, J.H.; Kim, H.K.; Lee, A.Y.; Lee, S.O.; Kim, Y.S.; Ryu, S.Y.; Kim, S.Y.; Lee, Y.J.; Ko, B.S. Anti-Platelet Effects of Bioactive Compounds Isolated from the Bark of Rhus Verniciflua Stokes. *J. Ethnopharmacol.* 2006, 106, 62–69. [CrossRef]

53. Lee, J.-S.; Cho, J.-H.; Lee, D.-S.; Son, C.-G. Genotoxicity Evaluation of an Ethanol Extract Mixture of Astragali Radix and Salviae miltiorrhizae Radix. *Evid. Based Complement. Alternat. Med.* 2018, 5684805. [CrossRef]

54. Kucharova, M.; Hronek, M.; Rybakova, K.; Zadak, Z.; Stetina, R.; Joskova, V.; Patkova, A. Comet assay and its use for evaluating oxidative DNA damage in some pathological states. *Physiol. Res.* 2019, 68, 1–15. [CrossRef]